Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and ...
C4X Discovery Holdings Ltd. has selected a preclinical candidate from its oral α4β7 integrin inhibitor program for the treatment of inflammatory bowel disease (IBD). The potent and selective α4β7 ...
Panelists discuss several promising new agents for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including an LPA1 receptor antagonist showing lung function ...
Multidisciplinary Oncology Center, University of Lausanne Hospitals, and the Swiss Institute for Experimental Cancer Research, National Center of Competence in Research Molecular Oncology, Epalinges, ...
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced interim data from its Phase 1 dose escalation clinical trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results